Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction

Sara Fuchs, Tali Feferman, Roberto Meidler, Raanan Margalit, Camille Sicsic, Talma Brenner, Orgad Laub, Miriam C. Souroujon

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review


Intravenous immunoglobulin (IVIG) administration has been beneficially used for the treatment of a variety of autoimmune diseases including myasthenia gravis (MG). We have demonstrated that IVIG administration in experimental autoimmune MG (EAMG) results in suppression of disease that is accompanied by decreased Th1 cell and B cell proliferation. Chromatography of pooled human immunoglobulins (IVIG) on immobilized IgG, isolated from rats with EAMG or from MG patients, results in a depletion of the suppressive activity of the IVIG. Moreover, reconstitution of the activity-depleted IVIG with the eluted minute IVIG fractions that had been adsorbed onto the EAMG- or MG-specific columns recovers the depleted immunosuppressive activity. This study supports the notion that the therapeutic effect of IVIG is mediated by an antigen-specific anti-immunoglobulin (anti-idiotypic) activity that is essential for its suppressive activity.

Original languageEnglish
Title of host publicationMyasthenia Gravis and Related Disorders 11th International Conference
PublisherBlackwell Publishing Inc.
Number of pages5
ISBN (Print)9781573316873
StatePublished - Jun 2008

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Experimental autoimmune myasthenia gravis (EAMG)
  • Fractionation
  • Immunotherapy
  • Intravenous immunoglobulin (IVIG)
  • Myasthenia gravis (MG)


Dive into the research topics of 'Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction'. Together they form a unique fingerprint.

Cite this